Emisphere Technologies and AAIPharma to Expand Use of Eligen Technology
Emisphere Technologies, Inc. (Cedar Knolls, NJ), a biopharmaceutical company that focuses on delivery of therapeutic molecules using its Eligen Technology, and AAIPharma, Inc. (Wilmington, NC), have formed a strategic alliance intended to expand the application of Emisphere' s Eligen Technology and AAIPharma's drug development services.
Emisphere Technologies, Inc. (Cedar Knolls, NJ), a biopharmaceutical company that focuses on delivery of therapeutic molecules using its Eligen Technology, and AAIPharma, Inc. (Wilmington, NC), have formed a strategic alliance intended to expand the application of Emisphere’ s Eligen Technology and AAIPharma’s drug development services.
Emisphere’s proprietary Eligen Technology is a delivery method for therapeutic molecules and nutritional supplements. These therapeutic molecules, both large and small, may be currently delivered by injection. The Eligen Technology can be applied by oral administration or other routes, such as buccal, rectal, inhalational, intra-vaginal, or transdermal.
AAIPharma, Inc. is a global provider of pharmaceutical product development services currently provides drug product formulation services to Emisphere.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
